Skip to content

Systemic Steroid Administration for Refractory ACNES

Exploratory Arial of Systemic Steroid Administration for Refractory Anterior Cutaneous Nerve Entrapment Syndrome (ACNES)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs061240098
Enrollment
5
Registered
2024-12-25
Start date
2025-03-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Cutaneous Nerve Entrapment Syndrome (ACNES)

Interventions

once daily by intravenous infusion. This is administered for 3 consecutive days.

Sponsors

Otsuka Yuki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Persons who meet all of the following criteria will be included in this study (1) Patients who are 18 years of age or older at the time of obtaining consent. (2) Patients who have received a thorough explanation of their participation in this study, and who have given written consent of their own free will based on sufficient understanding. (iii) Patients diagnosed with ACNES based on the criteria specified in the research protocol. 4) Patients who have been judged by several physicians familiar with the treatment of ACNES to be difficult to treat with standard treatments such as internal medicine therapy, nerve blocks, surgery, and pulsed radiofrequency therapy.

Exclusion criteria

Exclusion criteria: Patients who meet any of the following criteria will not be included in the study (1) Patients with contraindications to corticosteroid administration (2) Patients who are already using or have used systemic corticosteroids within 1 year due to other diseases (3) Patients for whom follow-up after administration is difficult. (4) Patients who have difficulty in assessing quality of life and pain due to their cognitive dysfunction, etc. (5) Patients who are judged not to be candidates for steroid administration based on the results of screening tests. (6) Other patients deemed inappropriate as research subjects by the principal investigator and subinvestigators.

Design outcomes

Primary

MeasureTime frame
Any adverse events related to the administration of Sol Medrol and how they were treated

Secondary

MeasureTime frame
1) Severity of symptoms: pain scale (patient reported VAS and physician reported VAS), quality of life (EuroQOL: EQ-5D-5L) 2) Area of pain (vertebral level, size) 3) Prescribed dose of analgesics 4) Existence of unscheduled medical visits 5) Vital signs

Contacts

Public ContactYuki Otsuka

Okayama University Hospital

otsuka@s.okayama-u.ac.jp+81-86-235-7342

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026